Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Jacob S, Varughese G Eye (Lond). 2024; 38(10):1787-1788.
PMID: 38341496 PMC: 11226659. DOI: 10.1038/s41433-024-02980-y.
Tirzepatide: A Systematic Update.
Forzano I, Varzideh F, Avvisato R, Jankauskas S, Mone P, Santulli G Int J Mol Sci. 2022; 23(23).
PMID: 36498958 PMC: 9741068. DOI: 10.3390/ijms232314631.
References
1.
. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2020; 44(Suppl 1):S111-S124.
DOI: 10.2337/dc21-S009.
View
2.
Davies M, Faerch L, Jeppesen O, Pakseresht A, Pedersen S, Perreault L
. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278):971-984.
DOI: 10.1016/S0140-6736(21)00213-0.
View
3.
Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B
. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515.
DOI: 10.1056/NEJMoa2107519.
View